These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 49083)
1. Letter: Variety in general practice. Jacobs P; Dubovsky D; King HS S Afr Med J; 1975 Apr; 49(16):650-1. PubMed ID: 49083 [No Abstract] [Full Text] [Related]
2. Therapeutic progress--review XII. Treatment of multiple myeloma. Oakley JE; Franklin IM J Clin Hosp Pharm; 1984 Mar; 9(1):15-20. PubMed ID: 6371060 [No Abstract] [Full Text] [Related]
3. [The effect of alkylating cytostatics on the development of secondary malignant tumors]. Galajda P; Donner L Vnitr Lek; 1984 Aug; 30(8):756-63. PubMed ID: 6506498 [No Abstract] [Full Text] [Related]
9. [Radiotherapeutic aspects of multiple myeloma]. Renner H Strahlentherapie; 1973 Jul; 146(1):15-23. PubMed ID: 4126404 [No Abstract] [Full Text] [Related]
10. The cyclic use of multiple alkylating agents in multiple myeloma. Harley JB; Ramanan SV; Kim I; Thiagarajan PV; Chen JH; Gomez R; Koppel D; Hyde F; Gustke S; Krall J W V Med J; 1972 Jan; 68(1):1-3. PubMed ID: 4500402 [No Abstract] [Full Text] [Related]
11. Letter: Myeloma cells after treatment with alkylating agents. Baccarani M; Santucci A Blood; 1975 Oct; 46(4):650-1. PubMed ID: 1174699 [No Abstract] [Full Text] [Related]
12. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma. Valeriote F; Grates H J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743 [TBL] [Abstract][Full Text] [Related]
13. Preleukemia. Reizenstein P Acta Med Scand; 1975 Dec; 198(6):433-5. PubMed ID: 1108599 [No Abstract] [Full Text] [Related]
14. [Guidelines in the therapy of various neoplastic diseases with cytostatic drugs]. Bollag W Praxis; 1969 Jun; 58(22):703-7. PubMed ID: 5258076 [No Abstract] [Full Text] [Related]
15. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Alberts DS; Durie BG; Salmon SE Cancer Treat Rep; 1977; 61(3):381-8. PubMed ID: 872138 [TBL] [Abstract][Full Text] [Related]
16. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma]. Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293 [No Abstract] [Full Text] [Related]
17. [Bone marrow protection by immunomodulators in antineoplastic chemotherapy]. De Vita F; Della Vittoria Scarpati M; Diadema MR; Pilerci N; Catalano G G Ital Chemioter; 1991; 38(1-3):205-6. PubMed ID: 1365595 [No Abstract] [Full Text] [Related]
18. Protein analyses in myelomatosis. Carter PM; Slater L; Lee J; Perry D; Hobbs JR J Clin Pathol Suppl (Assoc Clin Pathol); 1975; 6():45-53. PubMed ID: 802872 [No Abstract] [Full Text] [Related]
19. [Adverse events and those managements of alkylating agents]. Matsuoka H Nihon Rinsho; 2015 Feb; 73 Suppl 2():139-42. PubMed ID: 25831738 [No Abstract] [Full Text] [Related]